Xynomic Pharmaceuticals Holdings Inc represents a strong commitment to innovation and excellence in the pharmaceutical industry. The company's corporate philosophy focuses on developing and commercializing breakthrough oncology treatments to improve patients' lives. With a vision to become a global leader in precision medicine, Xynomic Pharmaceuticals prioritizes research and collaboration to unlock the full potential of targeted therapies. The company's core values include integrity, patient-centricity, and scientific rigor. By combining cutting-edge science with a dedication to clinical advancement, Xynomic Pharmaceuticals strives to make a meaningful impact in the field of oncology and bring hope to patients worldwide.

Xynomic Pharmaceuticals Holdings Inc is primarily present in the United States and China.

Xynomic Pharmaceuticals Holdings Inc has achieved significant milestones in its operations. The company successfully completed the Phase 1/2 clinical trials for its lead product candidate, abexinostat, a histone deacetylase inhibitor (HDACi). It has also obtained Fast Track designation from the U.S. FDA for abexinostat in combination with rituximab for the treatment of relapsed or refractory diffuse large B-cell lymphoma. Xynomic has received Orphan Drug Designation from the FDA for its other clinical-stage product, XP-102 (bucillamine), for the treatment of patients with non-alcoholic steatohepatitis. The company's achievements highlight its dedication to advancing innovative therapies for better patient outcomes.

Xynomic Pharmaceuticals Holdings Inc has a rich history and background in the pharmaceutical industry. Established in [insert year], the company has dedicated itself to the development of innovative therapies for various diseases. Xynomic Pharmaceuticals focuses on targeting unmet medical needs, prioritizing patient well-being and improved outcomes. With a strong emphasis on research and development, the company has actively pursued collaborations and partnerships to advance its pipeline of potential drugs. As a leader in the industry, Xynomic Pharmaceuticals continues to strive towards delivering breakthrough treatments that positively impact patients' lives.

The main competitors of Xynomic Pharmaceuticals Holdings Inc in the market include established pharmaceutical companies such as Pfizer, Novartis, Roche, and Johnson & Johnson. These multinational companies have a strong presence in the pharmaceutical industry and offer a wide range of therapeutic products and services. Xynomic Pharmaceuticals Holdings Inc competes with these companies by focusing on its innovative drug development pipeline and unique market positioning.

Xynomic Pharmaceuticals Holdings Inc is primarily active in the biopharmaceutical industry.

The business model of Xynomic Pharmaceuticals Holdings Inc is focused on developing innovative cancer treatments. The company aims to identify and license promising drug candidates, and then advance them through clinical trials and regulatory approval processes. Xynomic Pharmaceuticals uses a strategic approach that combines in-house development with collaborations and partnerships to maximize resources and expertise. By targeting unmet medical needs and leveraging its expertise in oncology, Xynomic Pharmaceuticals aims to bring new and effective treatments to patients worldwide.

De K/W-verhouding kan momenteel niet worden berekend voor Xynomic Pharmaceuticals Holdings.

De KUV kan momenteel niet worden berekend voor Xynomic Pharmaceuticals Holdings.

De AlleAktien Kwaliteitsscore voor Xynomic Pharmaceuticals Holdings is 4/10.

De omzet kan momenteel niet worden berekend voor Xynomic Pharmaceuticals Holdings.

De winst kan momenteel niet berekend worden voor Xynomic Pharmaceuticals Holdings.

Xynomic Pharmaceuticals Holdings Inc is a rising biotech company focused on developing novel therapies for treating various types of cancer. Its business model includes research and development, clinical trials, manufacturing, and distribution of drugs. The company's research and development department is the core of the organization, where experts work on identifying and developing new compounds to combat cancer cells. Clinical trials are conducted to investigate the efficacy and safety of promising drug candidates in humans. Manufacturing involves producing the drug once clinical trials are successfully completed, often in collaboration with external partners. Xynomic Pharmaceuticals currently does not have any drugs on the market but plans to seek FDA approval in the near future. The company has several promising drug candidates, including Abexinostat, XP-105, and XP-102, which have shown positive results in clinical trials. Overall, Xynomic Pharmaceuticals is an emerging biotech company dedicated to developing innovative cancer medications.

Xynomic Pharmaceuticals Holdings keert een dividend van 0 USD uit, verdeeld over betalingen per jaar.

De dividend kan momenteel niet worden berekend voor Xynomic Pharmaceuticals Holdings of het bedrijf keert geen dividend uit.

De ISIN van Xynomic Pharmaceuticals Holdings is US98421X1028.

De ticker van Xynomic Pharmaceuticals Holdings is XYNO.

Binnen de laatste 12 maanden betaalde Xynomic Pharmaceuticals Holdings een dividend van . Dit komt overeen met een dividendrendement van ongeveer . Voor de komende 12 maanden zal Xynomic Pharmaceuticals Holdings naar verwachting een dividend van 0 USD betalen.

De dividendrendement van Xynomic Pharmaceuticals Holdings is momenteel .

Xynomic Pharmaceuticals Holdings betaalt elk kwartaal een dividend uit. Dit wordt uitgekeerd in de maanden .

Xynomic Pharmaceuticals Holdings betaalde de afgelopen 0 jaar elk jaar dividend.

Voor de komende 12 maanden wordt een dividend van 0 USD verwacht. Dit komt overeen met een dividendrendement van 0 %.

Xynomic Pharmaceuticals Holdings wordt toegewezen aan de sector 'Gezondheid'.

Om het laatste dividend van Xynomic Pharmaceuticals Holdings van 3-10-2024 ter hoogte van 0 USD te ontvangen, moest je het aandeel voor de ex-datum op 3-10-2024 in je portefeuille hebben.

De laatste dividenduitkering vond plaats op 3-10-2024.

In het jaar 2023 heeft Xynomic Pharmaceuticals Holdings 0 USD aan dividenden uitgekeerd.

De dividenden van Xynomic Pharmaceuticals Holdings worden in USD uitgekeerd.